Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo
Shuxian Song1, Dan Liu, Jinliang Peng
1School of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai, PR China.
Abstract:
Epidermal growth factor receptor (EGFR) is an important anti-cancer therapy target that is applicable to many cancer types. We had previously reported the screening and discovery of a novel peptide ligand against EGFR named GE11. It was shown to bind to EGFR competitively with EGF and mediate gene delivery to cancer cells with high-EGFR expression. In this study, we conjugated GE11 on to liposome surface and examined their binding and distribution to EGFR expressing cancer cells in vitro and in vivo using fluorescence imaging techniques. GE11 liposomes were found to bind specifically and efficiently to EGFR high-expressing cancer cells. In vivo in H1299 xenograft mouse model, GE11 liposomes also extravasated and accumulated into the tumor site preferentially, and demonstrated better targeting and drug delivery capacities.
Insights
Researchers developed GE11 peptide-conjugated liposomes for targeted cancer therapy. These liposomes efficiently bind to epidermal growth factor receptor (EGFR)-expressing cancer cells, showing promising in vivo tumor accumulation and drug delivery capabilities.
Area of Science:
- Oncology
- Biotechnology
- Nanomedicine
Background:
- Epidermal growth factor receptor (EGFR) is a key target in anti-cancer therapies.
- The GE11 peptide ligand was previously discovered to bind EGFR competitively with EGF.
- GE11 mediates gene delivery to EGFR-expressing cancer cells.
Purpose of the Study:
- To conjugate the GE11 peptide onto liposomes.
- To evaluate the binding and distribution of GE11-conjugated liposomes to EGFR-expressing cancer cells in vitro and in vivo.
- To assess the potential of GE11 liposomes for targeted cancer therapy and drug delivery.
Main Methods:
- Conjugation of GE11 peptide to liposome surfaces.
- In vitro binding assays with EGFR-expressing cancer cells.
- In vivo studies using H1299 xenograft mouse models.
- Fluorescence imaging techniques for tracking liposome distribution.
Main Results:
- GE11 liposomes demonstrated specific and efficient binding to EGFR-high-expressing cancer cells.
- In vivo, GE11 liposomes preferentially extravasated and accumulated in tumor sites.
- The liposomes exhibited enhanced targeting and drug delivery capacities in the tumor model.
Conclusions:
- GE11-conjugated liposomes represent a promising targeted delivery system for EGFR-expressing cancers.
- This approach enhances drug delivery to tumors by leveraging the GE11 peptide's affinity for EGFR.
- Further development could lead to improved therapeutic strategies for various cancer types.
